ID: ALA1259188

Max Phase: Preclinical

Molecular Formula: C27H31FN8O

Molecular Weight: 502.60

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cn1nnc(Cc2ccc3c(c2)c(C2CCN(CCN4CCNC4=O)CC2)cn3-c2ccc(F)cc2)n1

Standard InChI:  InChI=1S/C27H31FN8O/c1-33-31-26(30-32-33)17-19-2-7-25-23(16-19)24(18-36(25)22-5-3-21(28)4-6-22)20-8-11-34(12-9-20)14-15-35-13-10-29-27(35)37/h2-7,16,18,20H,8-15,17H2,1H3,(H,29,37)

Standard InChI Key:  FGHKCRNDQSRICR-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 502.60

Molecular Weight (Monoisotopic): 502.2605

AlogP: 3.09

#Rotatable Bonds: 7

Polar Surface Area: 84.11

Molecular Species: BASE

HBA: 7

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 8.58

CX LogP: 3.88

CX LogD: 2.67

Aromatic Rings: 4

Heavy Atoms: 37

QED Weighted: 0.42

Np Likeness Score: -1.45

References

1. Kristensen JL, Püschl A, Jensen M, Risgaard R, Christoffersen CT, Bang-Andersen B, Balle T..  (2010)  Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for α(1)-adrenoceptors.,  53  (19): [PMID:20857909] [10.1021/jm100652h]

Source

Source(1):

• Scientific Literature